Related Experiment Video
Updated: Aug 5, 2026
10:25
Using the E1A Minigene Tool to Study mRNA Splicing Changes
Published on: April 22, 2021
Targeting EZH2 oncogenic splicing: decoding the regulatory network and antisense correction
Md Rafikul Islam1,2, Preeti Nagar1,2, Naomi McNaughton1
1Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA.
Genes & Development
|August 3, 2026
Summary
Targeting splicing factor mutations in cancer with antisense oligonucleotides (ASOs) corrects aberrant RNA splicing and nonsense-mediated decay (NMD), restoring tumor suppressor gene function and offering a new therapeutic strategy.
Area of Science:
- Molecular Biology
- Cancer Genetics
- RNA Biology
Background:
- Recurrent mutations in splicing factors (SFs) drive tumorigenesis in blood and solid cancers.
- SF mutations alter RNA binding, cause widespread splicing errors, and trigger nonsense-mediated mRNA decay (NMD).
- Dysregulation of hematopoietic genes due to SF mutations leads to blood cancers, with limited therapeutic options.
Purpose of the Study:
- To develop a gene-specific targeted therapy for SF-mutated cancers.
- To investigate the potential of antisense oligonucleotide (ASO) pharmacology for treating these cancers.
Main Methods:
- Identified and analyzed splicing cis-elements in the EZH2 tumor suppressor gene.
- Mapped regulatory protein interactions within splicing and NMD pathways.
- Designed and tested ASOs targeting key regulatory sites in EZH2 transcripts.
Main Results:
- The lead ASO effectively corrected aberrant splicing and NMD.
- Restored EZH2 expression and function.
- Partially rescued hematopoietic defects and cellular properties in a model system.
Conclusions:
- ASO pharmacology presents a viable and actionable strategy for clinical development in SF-mutated cancers.
- This approach challenges existing treatment paradigms for these malignancies.
